<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37683237</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><MedlineDate>2023 Sep-Oct 01</MedlineDate></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Treatment of Long-COVID Neuropsychiatric Sequelae Using Tricyclic Antidepressants: A Case Series.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>460</EndPage><MedlinePgn>458-460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001725</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>La Sala</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, NY Michael.Lasala@stonybrookmedicine.edu .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinfeld</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Constantino</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="Y">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37683237</ArticleId><ArticleId IdType="doi">10.1097/JCP.0000000000001725</ArticleId><ArticleId IdType="pii">00004714-202309000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine . 2021;38:101019.</Citation></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med . 2022;54:1473&#x2013;1487.</Citation></Reference><Reference><Citation>Nobile B, Durand M, Oli&#xe9; E, et al. The anti-inflammatory effect of the tricyclic antidepressant clomipramine and its high penetration in the brain might be useful to prevent the psychiatric consequences of SARS-CoV-2 infection. Front Pharmacol . 2021;12:615695.</Citation></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, et al. Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients. Intern Emerg Med . 2022;1&#x2013;9.</Citation></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry . 2021;8:130&#x2013;140.</Citation></Reference><Reference><Citation>Zawilska JB, Kuczy&#x144;ska K. Psychiatric and neurological complications of long COVID. J Psychiatr Res . 2022;156:349&#x2013;360.</Citation></Reference><Reference><Citation>Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of long COVID symptoms. Front Med . 2023;10:1011936.</Citation></Reference><Reference><Citation>Brundin L, Erhardt S, Bryleva EY, et al. The role of inflammation in suicidal behaviour. Acta Psychiatr Scand . 2015;132:192&#x2013;203.</Citation></Reference><Reference><Citation>Xia Z, DePierre JW, N&#xe4;ssberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology . 1996;34:27&#x2013;37.</Citation></Reference><Reference><Citation>Gonzalez-Martinez A, Guerrero-Peral &#xc1;L, Arias-Rivas S, et al. Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors. J Neurol . 2022;269:5702&#x2013;5709.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>